Alx Oncology Holdings (ALXO) Amortizatization of Intangibles (2022 - 2026)
Alx Oncology Holdings (ALXO) posted Amortizatization of Intangibles of $199000.0 for Q1 2026, up 6.99% sequentially from $186000.0 in Q4 2025, and down 62.17% YoY from $526000.0 in Q1 2025.
Analysis
Alx Oncology Holdings (ALXO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Alx Oncology Holdings has reported Amortizatization of Intangibles for 5 years, with the latest figure at $199000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 62.17% year-over-year to $199000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $915000.0 (down 74.79% YoY) and the FY2025 annual result came in at $1.2 million, down 73.33% from the prior year.
- Amortizatization of Intangibles advanced to $199000.0 in Q1 2026 per ALXO's latest filing, from $186000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $1.9 million in Q4 2023 and troughed at -$107000.0 in Q1 2022.
- A 5-year average of $795588.2 and a median of $684000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2025: Amortizatization of Intangibles soared 41150.0% in 2023, then plunged 79.14% in 2025.
- Over 5 years, Amortizatization of Intangibles stood at $684000.0 in 2022, then soared by 175.0% to $1.9 million in 2023, then slumped by 60.82% to $737000.0 in 2024, then tumbled by 74.76% to $186000.0 in 2025, then gained by 6.99% to $199000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $199000.0, $186000.0, and $219000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Alx Oncology Holdings | 272.64 Mn | 272.64 Mn | - | 341,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 341,000.00 |
| Mar 31, 2026 | 199,000.00 |
| Dec 31, 2025 | 186,000.00 |
| Sep 30, 2025 | 219,000.00 |
| Jun 30, 2025 | 311,000.00 |
| Mar 31, 2025 | 526,000.00 |
| Dec 31, 2024 | 737,000.00 |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.88 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 1.11 Mn |
| Dec 31, 2022 | 684,000.00 |
| Sep 30, 2022 | 359,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | -107,000.00 |